Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2023-08-04 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated 4th August 2023, informing about the availability of the audio recording of a conference call discussing the financial results for the quarter ended 30th June 2023. It references the SEBI Listing Obligations and Disclosure Requirements, indicating a regulatory compliance announcement. The document does not contain the transcript itself, nor detailed financial data, but rather directs readers to the company's website to access the recording. The length is only 1402 characters, which is quite short and consistent with an announcement rather than a full report or transcript. According to the rules, announcements about availability of conference call recordings are best classified as Regulatory Filings (RNS) because they do not contain the full transcript or substantive financial data themselves.
2023-08-04 English
Statement of deviation(s) or variation(s) under Reg. 32
Capital/Financing Update Classification · 95% confidence The document contains detailed tables and statements regarding the utilization of funds raised through a private placement of non-convertible debentures by Piramal Pharma Limited. It includes information on the amount raised, funds utilized, and any deviations or variations in the use of those funds. This type of content is characteristic of a Capital/Financing Update, as it focuses on fundraising activities and the deployment of raised capital. The document is relatively short (3185 characters) and does not present comprehensive financial statements or performance data, so it is not an Annual Report or Interim Report. It is not an announcement of a report publication but a substantive update on capital utilization. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-08-03 English
Investor Presentation
Interim / Quarterly Report Classification · 100% confidence The document is a press release and investor presentation announcing the unaudited financial results for the quarter ended June 30, 2023 (Q1FY24). It contains detailed financial highlights, business updates, and a conference call invitation for discussing the quarterly results. The document includes comprehensive financial data such as revenue, EBITDA, PAT, segment performance, and operational highlights. It also includes a detailed investor presentation with forward-looking statements and disclaimers. The presence of actual financial statements and substantive financial data for a quarter (Q1FY24) indicates this is an Interim / Quarterly Report. It is not merely an announcement or a brief summary but a full quarterly financial report with analysis and data. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2024
2023-08-03 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release and investor presentation announcing the unaudited financial results for the quarter ended June 30, 2023 (Q1FY24). It contains detailed financial highlights, business updates, and a conference call invitation for discussing the quarterly results. The document includes comprehensive financial data such as revenue, EBITDA, PAT, segment performance, and operational highlights. It also includes a detailed investor presentation with forward-looking statements and disclaimers. The presence of detailed quarterly financial data and analysis confirms this is a comprehensive interim/quarterly report rather than just a press release or announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2023-08-03 English
Outcome of Board Meeting
Regulatory Filings
2023-08-03 English
Financial Result Updates
Regulatory Filings
2023-08-03 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.